These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
189 related articles for article (PubMed ID: 3992527)
1. Fibrinogen Kawaguchi: an abnormal fibrinogen characterized by defective release of fibrinopeptide A. Matsuda M; Saeki E; Kasamatsu A; Nakamikawa C; Manabe S; Samejima Y Thromb Res; 1985 Feb; 37(3):379-90. PubMed ID: 3992527 [TBL] [Abstract][Full Text] [Related]
2. Fibrinogen Sapporo: dysfibrinogenemia characterized by the replacement of A alpha arginine-16 by histidine resulting in the delayed release of fibrinopeptide A by thrombin. Asakura S; Terukina S; Yamazumi K; Matsuda M; Murayama H; Higuchi A; Musashi M; Sakurada K; Miyazaki T Nihon Ketsueki Gakkai Zasshi; 1989 Sep; 52(6):1094-104. PubMed ID: 2588959 [TBL] [Abstract][Full Text] [Related]
3. A new congenital abnormal fibrinogen Ise characterized by the replacement of B beta glycine-15 by cysteine. Yoshida N; Wada H; Morita K; Hirata H; Matsuda M; Yamazumi K; Asakura S; Shirakawa S Blood; 1991 May; 77(9):1958-63. PubMed ID: 2018836 [TBL] [Abstract][Full Text] [Related]
5. Fibrinogen Bondy: a new case of dysfibrinogenemia. Isolation of the abnormal fibrinogen molecules. Jandrot-Perrus M; Aurousseau MH; Rabiet MJ; Josso F Thromb Res; 1982 Sep; 27(6):659-70. PubMed ID: 6217586 [TBL] [Abstract][Full Text] [Related]
6. Delayed release of an abnormal fibrinopeptide A from fibrinogen Manchester: effect of the A alpha 16 Arg leads to His substitution upon fibrin monomer polymerization and the immunological crossreactivity of the peptide. Lane DA; Southan C; Ireland H; Thompson E; Kehl M; Henschen A Br J Haematol; 1983 Apr; 53(4):587-97. PubMed ID: 6830702 [TBL] [Abstract][Full Text] [Related]
7. Fibrinogen Milano. VI: A heterozygous dysfibrinogenemia (A alpha 16 Arg----His) with bleeding tendency. Bögli C; Cofrancesco E; Cortellaro M; Della Volpe A; Hofer A; Furlan M; Zanussi C Eur J Haematol; 1990 Jul; 45(1):26-30. PubMed ID: 2379562 [TBL] [Abstract][Full Text] [Related]
8. Fibrinogen Barcelona II: a new case of A alpha 16 Arg----His substitution. Borrell M; Vila L; Solá J; Coll I; Fontcuberta J Haemostasis; 1990; 20(1):1-7. PubMed ID: 2323678 [TBL] [Abstract][Full Text] [Related]
10. ["Fibrinogen Kawaguchi": a hereditary dysfibrinogenemia characterized by defective release of fibrinopeptide A associated with altered polymerization of fibrin monomers]. Saeki E; Matsuda M; Ichinose A; Samejima Y; Kasamatsu A; Ara R; Mitsuno K; Kihara T; Hara Y Nihon Ketsueki Gakkai Zasshi; 1985 Aug; 48(5):1229-35. PubMed ID: 4072586 [No Abstract] [Full Text] [Related]
11. Fibrinogen New Orleans: hereditary dysfibrinogenemia with an A alpha chain abnormality. Andes WA; Chavin SI; Beltran G; Stuckey WJ Thromb Res; 1982 Jan 1-15; 25(1-2):41-50. PubMed ID: 6801812 [TBL] [Abstract][Full Text] [Related]
12. Fibrinogen Seattle II: defective release of fibrinopeptide A in a slow clotting fibrinogen. Schreiber WE; Schmer G Thromb Res; 1985 Jan; 37(1):45-52. PubMed ID: 3983901 [TBL] [Abstract][Full Text] [Related]
13. Fibrinogen Milano II: a congenital dysfibrinogenaemia associated with juvenile arterial and venous thrombosis. Haverkate F; Koopman J; Kluft C; D'Angelo A; Cattaneo M; Mannucci PM Thromb Haemost; 1986 Feb; 55(1):131-5. PubMed ID: 3705000 [TBL] [Abstract][Full Text] [Related]
14. Two cases of dysfibrinogenemia characterized by abnormal FPB release: fibrinogen Madrid I & II. Borrell M; Vila L; Solá J; Coll I; Gómez N; González N; Rutllant ML Thromb Res; 1987 Mar; 45(5):591-9. PubMed ID: 3109061 [TBL] [Abstract][Full Text] [Related]
15. An abnormal fibrinogen with delayed fibrinopeptide A release. Lane DA; VanRoss M; Kakkar VV; Bottomley KJ; Dhir K; Holt LP; MacIver JE Br J Haematol; 1980 Sep; 46(1):89-98. PubMed ID: 7426452 [TBL] [Abstract][Full Text] [Related]
16. "Fibrinogen Tokyo II". An abnormal fibrinogen with an impaired polymerization site on the aligned DD domain of fibrin molecules. Matsuda M; Baba M; Morimoto K; Nakamikawa C J Clin Invest; 1983 Sep; 72(3):1034-41. PubMed ID: 6886002 [TBL] [Abstract][Full Text] [Related]
17. Fibrinogen Barcelona I. Congenital dysfibrinogenemia characterized by defective release of fibrinopeptide A and fibrinogen degradation products. Vila V; Regañón E; Aznar J; Navarro G; Salas M Thromb Res; 1987 Mar; 45(5):437-49. PubMed ID: 2954261 [TBL] [Abstract][Full Text] [Related]
18. Fibrinogen Guarenas I: partial characterization of a new dysfibrinogenemia with an altered rate of fibrinopeptide release and an impaired polymerization. Lundberg UG; Rodriguez S; Marchi R; Ruiz-Saez A; Arocha-Piñango CL Thromb Res; 1995 Apr; 78(2):95-106. PubMed ID: 7482436 [TBL] [Abstract][Full Text] [Related]
19. Dysfibrinogenaemia characterized by abnormal fibrin monomer polymerization and normal fibrinopeptide A release. Lane DA; Cuddigan B; VanRoss M; Kakkar VV Br J Haematol; 1980 Mar; 44(3):483-94. PubMed ID: 6769460 [TBL] [Abstract][Full Text] [Related]
20. [Fibrinogen Bern III: a further case of hereditary fibrinogen variants with substitution A alpha 16 Arg----Cys]. Furlan M; Leupin L; Biasiutti FD; Lämmle B Schweiz Med Wochenschr; 1991 Jul; 121(29):1068-71. PubMed ID: 1891701 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]